Cetuximab antibody | AbD19834_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti cetuximab (clone AbD19834_hIgG1) at a concentration of 2 μg/ml and QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtiter plate was coated over night with human IgG1/kappa, human IgG1/lambda, rituximab or cetuximab at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using Human anti cetuximab (clone AbD19834, HCA220 - the monovalent format of MCA222) titrated to the given concentrations in PBST+10% human serum, followed by Mouse anti histidine tag:HRP (MCA5995P) in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate.
A microtitre plate was coated over night with cetuximab at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti cetuximab antibodies, clone AbD19834_hIgG1 (HCA222, blue line), clone AbD19830_hIgG1 (HCA221, green line) or clone AbD19815_hIgG1 (HCA223, red line). Detection was performed using HRP-conjugated cetuximab followed by QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the cetuximab used in this assay was performed using a LYNX Rapid HRP Conjugation Kit.
Human anti Cetuximab
- Product Type
- Monoclonal Antibody
- Clone
- AbD19834_hIgG1
- Isotype
- IgG1
- Specificity
- Cetuximab
Antibody Quality and Performance Guarantee
| Human anti Cetuximab, clone AbD19834_IgG1, is an anti-idiotypic antibody that binds specifically to cetuximab and inhibits the binding of the drug to its target, epidermal growth factor receptor (EGFR). It can be used in bioanalytical assays to measure the levels of cetuximab and biosimilar products in preclinical research and clinical trials. Human anti Cetuximab, clone AbD19834_IgG1 is a fully human antibody and is particularly suited as a calibrator for immune response assays to measure the anti-drug antibody (ADA) levels in patient sera. Cetuximab (brand name Erbitux®) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody is directed against EGFR and inhibits tumor cell proliferation by blocking the interaction of epidermal growth factor (EGF) with its receptor. View a summary of all anti cetuximab antibodies. |
|
- Product Form
- Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line. This product is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Source
- HKB-11
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Immunogen
- Cetuximab.
- Affinity
- The monovalent intrinsic affinity of Human anti Cetuximab, clone AbD19834_hIgG1 is KD = 0.5 nM as measured by real time, label free molecular interaction analysis on immobilized Cetuximab.
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Erbitux is a trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.
- ELISA
- This product is suitable for use in direct ELISA applications or as a bridging reagent in ADA assays.
Protocol: PK bridging ELISA to measure free drug.
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Hispec Assay Diluent | ||||||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | LYNX Rapid HRP Antibody Conjugation Kit | ||||||
Further Reading
-
Gomez, D. et al. (2013) Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?
Int J Surg. 11 (7): 507-13.
HCA222
151062
154990
167940
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with CETUXIMAB specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up